All intelligent investing is value investing – acquiring more than you are paying for.

Charlie Munger

Investor Portal

What we offer

Reasons to invest

  • Addressing areas of high unmet medical need:
    • Immuno-OncologyPrimary focus on advanced gastrointestinal tumors without surgical option
    • Vaccination: For protection against newly emerging or re-emerging infectious diseases
  • Unique safety profile based on measles vaccine backbone that is in use for vaccination against measles
  • Highly targeted approach offers patient-specific treatment options based on platform technology
  • Unlimited versatility of platform allows targeting of different indications across markets
  • Attractive exit opportunities with high return on investment in reasonable time

Markets

Targeting largest drug market segments
Immuno-Oncology market drivers
  • Cancer remains a global burden with increasing number of cancer-related deaths
  • Focus on innovative treatments that reduce reappearance of cancer
  • Clinical success of immunotherapeutics induced paradigm shift in cancer therapy
Vaccine market drivers
  • Increasing global supply causes escalating demand for vaccines
  • Start of governmental vaccination programs to eradicate endemic diseases
  • Launch of novel and innovative vaccine technologies
Global Immuno-Oncology market expectation
Global Vaccine market expectation
0
bn USD by 2026
0 %
CAGR
0
bn USD by 2026
0 %
CAGR

Favourable Risk Profile

  • Cutting-edge technology with induction of potent multifunctional immunological signatures
  • Unique and scalable production capabilities by proprietary manufacturing procedure that allows commercialization
  • Extensive technology experience acquired in 15 years of research & development of measles-vectored therapeutics
  • Diversified portfolio increases probability of success
  • High-class network established for swift clinical translation
  • Significantly mitigated risk of failure by opportunities across different markets

Contact

If you are interested in investing in CanVirex AG or would like to receive more information on our products and technology, please get in touch with us.